{"url_path":"/sec/vtgn/8-k/2026-06-09/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-09","source_url":"https://www.sec.gov/Archives/edgar/data/1411685/0001628280-26-041962-index.html","accession_number":"0001628280-26-041962","cik":"0001411685","ticker":"VTGN","issuer_name":"Vistagen Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1411685/0001628280-26-041962-index.html","primary_entity_key":"0001411685","primary_entity_name":"Vistagen Therapeutics, Inc."},"word_count":83,"has_tables":true,"body_markdown":"Item 8.01 Other Events.\n\nOn June 9, 2026, Vistagen Therapeutics, Inc. (the “Company”) issued a press release to announce that the Company’s clinical program for fasedienol nasal spray for the acute treatment of social anxiety disorder has achieved the minimum patient exposures as recommended under ICH E1, the international regulatory standard governing safety database exposure recommendations for drugs intended for long-term treatment of non-life-threatening conditions. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1."}